Vaccinex, Inc. Gains 30.13%
Vaccinex, Inc. (VCNX:NASDAQ) jumped higher at $6.78, a gain of 30.1%. On Fri, May 31, 2024, VCNX:NASDAQ touched a New 2-Week High of $6.78. The stock got featured on our News Catalysts scanner on Thu, May 16, 2024 at 10:11 AM in the 'BIOTECH' category. From Fri, May 17, 2024, the stock recorded 44.44% Up Days and 60.00% Green Days
About Vaccinex, Inc. (VCNX:NASDAQ)
Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. Its lead product candidate VX15 is in clinical development for the treatment of NSCLC, osteosarcoma and Huntington's disease and additional product candidates VX5 and VX25 are in earlier stages of development.
Top 10 Gainers:
- Ault Disruptive Technologies Corporation (ADRT:NYSEMKT), 233.33%
- Brand Engagement Network Inc Com (BNAI:NASDAQ), 110.85%
- Portage Biotech Inc. (PRTG:NASDAQ), 91.56%
- SRAX, Inc. (SRAX:NASDAQ), 80%
- FOXO Technologies Inc. Class A (FOXO:NYSEMKT), 39.51%
- XChange TEC.INC American Depositary Shares (XHG:NASDAQ), 31.5%
- Selina Hospitality PLC (SLNA:NASDAQ), 31.15%
- Cyclacel Pharmaceuticals, Inc. (CYCC:NASDAQ), 30.69%
- Vaccinex, Inc. (VCNX:NASDAQ), 30.13%
- Genprex, Inc. (GNPX:NASDAQ), 29.05%